Global Digital Dose Inhalers Market - 2023-2030

Global Digital Dose Inhalers Market - 2023-2030

Global Digital Dose Inhalers Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.

Digital dose inhalers are breathing aids that can be linked to electronic devices to check on a patient's health every day. These are especially helpful for people with respiratory diseases like asthma or obstructive diseases. Sensors in these inhalers prompt the user to take medicine at the appropriate times each day.

Digital dose inhaler health systems use electromechanical sensors and microelectronics to monitor inhaler actuation. Some gadgets include a linked smartphone, a mobile app that communicates with the patient, a cloud server, and a portal for the physician to see dashboard data.

Some digital dose inhalers can measure pollution or pollen levels or alarm patients if they forget them. Smart inhalers notify patients of missed or repeated doses and remind them to take their dosages on time, automatically, and easily.

Market Dynamics: Drivers and Restraints

Rise in prevalence of respiratory diseases

The rise in the prevalence of respiratory disease is one of the key drivers that helps the market to grow during the forecast period. Since the rise in respiratory diseases like asthma and COPD the use of digital dose inhaler devices is often used rapidly which indeed will increase the market growth.

For instance, according to the Centers for Disease Control and Prevention COPD affects an estimated 200 million people, with 3.2 million dying each year, making it the third-leading cause of mortality globally.

Asthma is one of the most common noncommunicable illnesses, impacting 262 million people worldwide. With almost 2.2 million new instances of lung cancer expected in 2022 and 1.80 million fatalities, lung cancer accounts for one in every four cancer deaths worldwide. Lower respiratory tract infection or pneumonia is a prominent cause of death, accounting for more than 2.4 million fatalities each year, primarily in low and middle-income countries (LMICs). COVID-19 has significantly increased pneumonia fatalities worldwide.

Furthermore, technological advancements in technological advancements in inhalers, Data-Driven Healthcare, the rise in the prevalence of the geriatric population, and rise in the telemedicine’s and others will further drive the market during the forecast period.

Market Dynamics: Restraint

Many restraint factors hampers the market growth during the forecast period some of the mare like, increasing medication cost and high cost associated with devices, privacy and data security concerns, regulatory hurdles, and lack of awareness among people regarding advanced treatment and devices available for asthma are going to impede the market growth.

Segment Analysis

The global digital dose inhalers is segmented based on product type, type, application, type, distribution channel and region.

The metered-dose inhaler from the device type segment accounted for approximately 41.2% of the market share

The metered-dose inhaler from the device type segment accounted for 41.2% and it is expected to be dominated during the forecast period. A metered-dose inhaler has a pressurized canister of medication that fits into a mouthpiece. In most instances, a dose of medication is released into your lungs by pushing the canister into the mouthpiece. Another type releases medication automatically when you inhale. Some metered-dose inhalers have counters that track how many doses remain.

For instance, on July 2023, Hormosan Pharma GmbH (Hormosan), Lupin’s wholly-owned subsidiary in Germany, stated that they have been launched Luforbec 100/6 (beclometasone 100µg / for motel 6µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Moreover, on February 8 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, stated the launch of HeroTracker Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device.

HeroTracker Sense is designed to help improve the lives of patients around the world suffering from chronic respiratory diseases such as asthma, COPD, Cystic Fibrosis and other respiratory conditions caused by COVID-19, to track their usage and facilitate improved adherence to their prescribed therapy.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to rigorous research and development activities and increased awareness regarding the currently available hi-tech respiratory devices. In addition, an upsurge in the prevalence of respiratory conditions among both the pediatric and elderly populations will boost the market growth over the forecast years.

For instance, in September 2020, Teva Pharmaceuticals launched the AirDuo Digihare and ArmonAir Digihaler inhalation powder, two digital maintenance inhalers for patients with asthma.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global digital dose inhalers market importantly on asthma for instance, according to the article titled ""Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a National Incident Cohort Study"" published in January 2022 adults with asthma were found to be at an increased risk of COVID-19 hospital admission compared with those without asthma conditions. Thus, increasing cases of COVID-19 are raising the cases of respiratory disorders which generates the need for digital dose inhalers.

Competitive Landscape

The major global players in the digital dose inhalers market include Novartis International AG, Propeller Health, H&T Presspart Manufacturing Ltd, AptarGroup Inc, Amiko Digital Health Limited, Trudell Medical UK Limited, ReciPharm, Sensirion, Teva Pharmaceuticals, Cohero Health, Inc and among others

Key Developments

 In February 2022, AstraZeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less global warming potential than propellants currently used in respiratory medicines.

 In October 2020, Zydus launched a pressurised Metered Dose Inhaler for COPD patient.

Why Purchase the Report?
• To visualize the global digital dose inhalers market segmentation-based device type, application, type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of digital dose inhalers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global digital dose inhalers market report would provide approximately 69 tables, 70 figures, and 185 Pages.



Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies